In-Vitro Colorectal Cancer Screening Tests Market Size, Share, Growth Analysis, By Test Type (Fecal Occult Blood Tests, Biomarker Tests), By End User (Hospitals, Clinics), By Region - Industry Forecast 2026-2033

In-Vitro Colorectal Cancer Screening Tests Market size was valued at USD 1.38 Billion in 2024 and is poised to grow from USD 1.47 Billion in 2025 to USD 2.44 Billion by 2033, growing at a CAGR of 6.5% during the forecast period (2026–2033).

The existence of several international players defines the global market. To increase their market share, businesses use a variety of techniques, including partnerships, agreements, regional growth, mergers, acquisitions, and new product creation. In our in-vitro colorectal cancer screening tests market reports, some of the leading quality in-vitro colorectal cancer screening tests manufacturers are as follows: Abbott (US), F. Hoffmann-La Roche AG (Switzerland), Quest Diagnostics (US), Sysmex Corporation (Japan), Siemens Healthcare (Germany), Alere Inc. (US), Eiken Chemical (Japan), Siemens AG (Germany), OncoCyte Corporation-Biotime (US), Merck KGaA (Germany). 'Abbott Laboratories ', 'Beckman Coulter Inc ', 'Eiken Chemical Co., Ltd. ', 'Epigenomics ', 'Sysmex Corporation ', 'Siemens Healthcare GmbH ', 'Quest Diagnostics Incorporated ', 'OncoCyte Corporation ', 'Merck KGaA ', 'Immunostics Inc. ', 'Kyowa Kirin Co. Ltd. ', 'Randox Laboratories Ltd. ', 'R-Biopharm AG ', 'Bio-Rad Laboratories, Inc ', 'Exact Sciences Corporation ', 'F. Hoffmann-La Roche AG ', 'Genomic Health, Inc ', 'Hologic, Inc. ', 'Illumina, Inc. ', 'Invitae Corporation'

The prevalence of colorectal cancer (CRC) is increasing as a result of numerous causes, including the ageing population, the adoption of an unhealthy lifestyle, and diabetes.

One of the main factors propelling the market's expansion is the rising frequency of colorectal cancer among the general population. Additionally, growing public awareness of the advantages of early cancer detection and prompt treatment is favourably affecting market expansion. The market is expanding as a result of numerous technological developments, such as the inclusion of genetic testing in cancer screening tests. These tests support early detection, the creation of treatment regimens, stopping the spread of cancerous cells, and lowering the dangers of afflicted conditions.

The North American, European, Asian-Pacific, Latin American, and Middle Eastern regions of the market for in-vitro colorectal cancer screening tests were used to split the market for regional analysis. In-vitro testing for colorectal cancer were the market leader in 2021 in North America.